- Next FDA user fee deal is under review at the White HouseThe White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sour…Endpoints · 2mo ago↗ source
- Post-Hoc: Lilly gets more secretive and hides Phase 1 pipelineEli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings pres…Endpoints · 2mo ago↗ source
- Replimune takes third swing at cancer drug approval following ‘productive’ FDA talksA twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.